Literature DB >> 24142590

Treatment of dystonia.

Mary Ann Thenganatt1, Joseph Jankovic.   

Abstract

Selecting the appropriate treatment for dystonia begins with proper classification of disease based on age, distribution, and underlying etiology. The therapies available for dystonia include oral medications, botulinum toxin, and surgical procedures. Oral medications are generally reserved for generalized and segmental dystonia. Botulinum toxin revolutionized the treatment of focal dystonia when it was introduced for therapeutic purposes in the 1980s. Surgical procedures are available for medication-refractory dystonia, markedly affecting an individual's quality of life.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24142590      PMCID： PMC3899473          DOI： 10.1007/s13311-013-0231-4

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  142 in total

1.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

Review 2.  Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain.

Authors:  P M Brennan; I R Whittle
Journal:  Br J Neurosurg       Date:  2008-08       Impact factor: 1.596

3.  Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations.

Authors:  Michael Turner; Ha Son Nguyen; Aaron A Cohen-Gadol
Journal:  J Neurosurg Pediatr       Date:  2012-08-03       Impact factor: 2.375

4.  Use of pallidal deep brain stimulation in postinfarct hemidystonia.

Authors:  Jennifer Witt; Phillip A Starr; Jill L Ostrem
Journal:  Stereotact Funct Neurosurg       Date:  2013-03-26       Impact factor: 1.875

5.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

6.  Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.

Authors:  D D Troung; M Rontal; M Rolnick; A E Aronson; K Mistura
Journal:  Laryngoscope       Date:  1991-06       Impact factor: 3.325

7.  Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration.

Authors:  Martin Krause; Wolfgang Fogel; Volker Tronnier; Sabine Pohle; Konstanze Hörtnagel; Ute Thyen; Jens Volkmann
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

8.  Deep brain stimulation in DYT1 dystonia: a 10-year experience.

Authors:  Fedor Panov; Yakov Gologorsky; Grayson Connors; Michele Tagliati; Joan Miravite; Ron L Alterman
Journal:  Neurosurgery       Date:  2013-07       Impact factor: 4.654

9.  Dopa-responsive dystonia: long-term treatment response and prognosis.

Authors:  T G Nygaard; C D Marsden; S Fahn
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

10.  A case of secondary dystonia responding to levodopa.

Authors:  Geneviève Bernard; Michel Vanasse; Sylvain Chouinard
Journal:  J Child Neurol       Date:  2009-10-06       Impact factor: 1.987
View more
  19 in total

1.  Editorial: Neurotherapeutics of movement disorders.

Authors:  Stewart A Factor; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Dystonia and leveraging oral pharmacotherapy.

Authors:  Michelle Ann C Sy; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-20       Impact factor: 3.575

Review 3.  An update on the use of botulinum toxin therapy in Parkinson's disease.

Authors:  Reversa Mills; Laxman Bahroo; Fernando Pagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 4.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

5.  MR Imaging of the Brain in Neurologic Wilson Disease.

Authors:  X-E Yu; S Gao; R-M Yang; Y-Z Han
Journal:  AJNR Am J Neuroradiol       Date:  2019-01       Impact factor: 3.825

6.  Cervical dystonia and substance abuse.

Authors:  Abhimanyu Mahajan; Joseph Jankovic; Laura Marsh; Achint Patel; H A Jinnah; Cynthia Comella; Richard Barbano; Joel Perlmutter; Neepa Patel
Journal:  J Neurol       Date:  2018-03-22       Impact factor: 4.849

Review 7.  Recent developments in dystonia.

Authors:  Hyder A Jinnah; Jan K Teller; Wendy R Galpern
Journal:  Curr Opin Neurol       Date:  2015-08       Impact factor: 5.710

Review 8.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

9.  Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.

Authors:  Anthony M Downs; Xueliang Fan; Christine Donsante; H A Jinnah; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

10.  Deep brain stimulation for dystonia.

Authors:  Wei Hu; Matt Stead
Journal:  Transl Neurodegener       Date:  2014-01-21       Impact factor: 8.014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.